医学
缺铁
肺动脉高压
心力衰竭
内科学
疾病
冠状动脉疾病
心脏病学
人口
贫血
环境卫生
作者
Stephan von Haehling,Ewa A. Jankowska,Dirk J. van Veldhuisen,Piotr Ponikowski,Stefan D. Anker
标识
DOI:10.1038/nrcardio.2015.109
摘要
Iron deficiency is very common worldwide, and has detrimental effects in individuals with cardiovascular disease. Correction of iron deficiency via intravenous iron supplementation results in symptomatic improvement in patients with heart failure, and improved exercise capacity in patients with pulmonary hypertension, but iron administration after cardiac transplantation surgery is contraindicated. Iron deficiency affects up to one-third of the world's population, and is particularly common in elderly individuals and those with certain chronic diseases. Iron excess can be detrimental in cardiovascular illness, and research has now also brought anaemia and iron deficiency into the focus of cardiovascular medicine. Data indicate that iron deficiency has detrimental effects in patients with coronary artery disease, heart failure (HF), and pulmonary hypertension, and possibly in patients undergoing cardiac surgery. Around one-third of all patients with HF, and more than one-half of patients with pulmonary hypertension, are affected by iron deficiency. Patients with HF and iron deficiency have shown symptomatic improvements from intravenous iron administration, and some evidence suggests that these improvements occur irrespective of the presence of anaemia. Improved exercise capacity has been demonstrated after iron administration in patients with pulmonary hypertension. However, to avoid iron overload and T-cell activation, it seems that recipients of cardiac transplantations should not be treated with intravenous iron preparations.
科研通智能强力驱动
Strongly Powered by AbleSci AI